首页 | 本学科首页   官方微博 | 高级检索  
     


Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials
Authors:C. Paul  L. Guenther  H. Torii  H. Sofen  R. Burge  C.Y. Lin  A. Potts Bleakman  L. Mallbris  Y. Poulin
Affiliation:1. Dermatology Department, Toulouse University and Larrey Hospital, Toulouse, France;2. Western University, London, ON, Canada;3. Guenther Research Inc., London, ON, Canada;4. Division of Dermatology, Tokyo Yamate Medical Center, Tokyo, Japan;5. Department of Medicine (Dermatology), David Geffen School of Medicine, Los Angeles, CA, USA;6. Eli Lilly and Company, Indianapolis, IN, USA;7. Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH, USA;8. Laval University and Centre de Recherche Dermatologique du Quebec Metropolitain, Quebec City, QC, Canada
Abstract:
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号